


Supplementary Figure S1



Paired progression-free intervals in the 29-patient PFS-ratio cohort. PFS1 denotes the immediately preceding systemic line; observed PFS2 denotes the MoFa-guided line. Arrowheads indicate censored observations (P7, P38 and P73).

Molecular Tumor Board in Advanced Sarcoma: Treatment Implementation and Clinical Outcomes in a Real-World Cohort

Journal of Cancer Research and Clinical Oncology

Christoph Weinfurter, Moritz Kaupp-Merkle, Ralf Marienfeld, Uwe Gerstenmaier, Jakob Niewöhner, Tobias Kolb, Axel Fürstberger, Sonja Dahlum, Paul Herzog, Ambros J. Beer, Regine Mayer-Steinacker, Meinrad Beer, Thomas F.E. Barth, Thomas Seufferlein, Nadine T. Gaisa, Mathias Wittau, Stephan Stilgenbauer, Alexandra von Baer, Markus Schultheiß, Reiner Siebert, Wolfgang Thaiss, Hartmut Döhner, Verena I. Gaidzik

Corresponding author: Verena I. Gaidzik, Department of Internal Medicine III, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany. Email: verena.gaidzik@uniklinik-ulm.de